MUC1* antibodies
The present describes monoclonal antibody to MUC1*.
1. A monoclonal antibody that binds to PSMGFR of SEQ ID NO:1, comprising an amino acid sequence in the heavy chain variable region comprising the following:
in the CDR1 region GYAMS (SEQ ID NO:172);
in the CDR2 region TISSGGTYIYYPDSVKG (SEQ ID NO:198); and
in the CDR3 region LGGDNYYEY (SEQ ID NO:224); and
an amino acid sequence in the light chain variable region comprising the following:
in the CDR1 region RASKSVSTSGYSYMH (SEQ ID NO:108);
in the CDR2 region LASNLES (SEQ ID NO:129); and
in the CDR3 region QHSRELPFT (SEQ ID NO:149).
2. The monoclonal antibody according to claim 1 , which is humanized.
3. An isolated nucleic acid encoding the monoclonal antibody according to claim 1 .
4. An isolated hybridoma expressing the monoclonal antibody according to claim 1 .
5. The antibody according to claim 1 , which is monovalent, an Fab, or a single chain variable fragment antibody (scFv).
6. The antibody according to claim 1 , which is bi-valent, bi-specific, or tri-specific.
7. The antibody according to claim 6 , wherein a portion of the antibody binds to MUC1* and another portion binds to a tumor-specific antigen on a cell surface.
8. The antibody according to claim 1 , which is fused to a chemical or a protein.
9. The antibody according to claim 8 , wherein the protein is a toxin, or a cytokine.
10. A method of treating MUC1* expressing cancer in a patient comprising administering the antibody according to claim 1 to the patient suffering from the cancer.
11. A monoclonal antibody that binds to PSMGFR of SEQ ID NO:1, comprising an amino acid sequence in the heavy chain variable region comprising the following:
in the CDR1 region RYGMS (SEQ ID NO:173);
in the CDR2 region TISSGGTYIYYPDSVKG (SEQ ID NO:199); and
in the CDR3 region DNYGSSYDYA (SEQ ID NO:225); and
an amino acid sequence in the light chain variable region comprising the following:
in the CDR1 region SATSSVSYIH (SEQ ID NO:109);
in the CDR2 region STSNLAS (SEQ ID NO:130); and
in the CDR3 region QQRSSSPFT (SEQ ID NO:150).
12. The monoclonal antibody according to claim 11 , which is humanized.
13. An isolated nucleic acid encoding the monoclonal antibody according to claim 11 .
14. An isolated hybridoma expressing the monoclonal antibody according to claim 11 .
15. The antibody according to claim 11 , which is monovalent, an Fab, or a single chain variable fragment antibody (scFv).
16. The antibody according to claim 11 , which is bi-valent, bi-specific, or tri-specific.
17. The antibody according to claim 16 , wherein a portion of the antibody binds to MUC1* and another portion binds to a tumor-specific antigen on a cell surface.
18. The antibody according to claim 11 , which is fused to a chemical or a protein.
19. The antibody according to claim 18 , wherein the protein is a toxin, or a cytokine.
20. A method of treating MUC1* expressing cancer in a patient comprising administering the antibody according to claim 11 to the patient suffering from the cancer.